Pharmaceutical Care for One Advanced Non-small Cell Lung Cancer Complicated with Severe Anemia

Abstract

Abstract: Objective To explore clinical pharmacists participating in the anti-tumor drug treatment methods and thoughts. Methods Through a case of advanced non-small cell lung cancer chemotherapy leading to severe anemia, the reasons of anaemia were analyzed, and the pharmacist experiences of helping physicians improve relevant treatment methods, paying attention to drug adverse reactions and guiding medication were introduced. It was considered that the rapidly progressing of disease was related to recombinant human erythropoietin by searching literatures, and relevant information was provided to the clinician. Results Clinical pharmacists participated in antitumor drug therapy with professional skills so that anemia of the patient relieved. It was acknowledged by the healthcare professionals, and the rational drug use was promoted. Conclusion In the process of clinical practice, clinical pharmacists should fully disclose the benefits and risks of drugs to the doctors and patients, and provide good drug information for clinicians, so as to ensure patients' medication to be safe, effective and reasonable.

Key words: clinical pharmacist, anemia, recombinant human erythropoietin

CLC Number:

R969.3

ZHOU Dian-you, XI Jia-xi, GONG Qian. Pharmaceutical Care for One Advanced Non-small Cell Lung Cancer Complicated with Severe Anemia[J]. Chinese Journal of Pharmacovigilance, 2016, 13(12): 757-760.

References

[1] Depierre A, Lagrange J L, Theobald S, et al. Standards, options and recommendations for the management of non small cell lung carcinoma[J]. Bull Cancer 2003, 90(2):151-166.
[2] Groopman J E, Itri L M. Chemotherapy-induced anemia in adults: incidence and treatment[J]. J Natl Cancer Inst, 1999, 91(19):1616-1634.
[3] Glaspy J,Degos L,Dicato M,et al. Comparable efficacy of epoetinalfa for anemic cancer patients receiving platinum and nonplatinum-based chemotherapy:a retrospective subanalysis of two large, community-based trials[J]. The Oncologist, 2002, 7(2):126-135.
[4] 王静, 李峻岭, 石远凯. 吉西他滨联合顺铂在非小细胞肺癌辅助化疗中的应用[J].中国全科医学, 2012, 15 (3C): 987-989.
[5] 王伟兰, 陈超, 郭代红. 吉西他滨相关性贫血的主动监测研究[J].中国药物应用与监测, 2014, 1(1): 29-31.
[6] Wood P A, Hrushkesky W J M. Cisplatin -associated anemia: an erythropoietin deficiency syndrome[J]. J Clin Invest , 1995, 95( 4):1650-1659.
[7] 中华人民共和国卫生部. 临床输血计数指南——内科输血指南[J]. 中国临床医师, 2001, 29(3): 29-30.
[8] CSCO肿瘤相关性贫血专家委员会. 肿瘤相关性贫血临床实践指南（2012-2013版）[EB/OL]. (2012-09)[2015-06-01].http://d.dxy.cn/detail/5913390.
[9] NCCN. NCCN Clinical practice guidelines in oncology. Cancer and chemotherapy induced anemia(2015.v1)[EB/OL]. (2014-06-26)[2015-06-25].http://www.nccn.org.
[10] 张艳华. 肿瘤相关性贫血治疗现状与药学监护[C]// 临床药学高端论坛之二十三肿瘤相关性贫血的治疗现状与药学监护讲义. 2012.
[11] Crawford J, Demetri G D, Gabrilove J L, et al. Clinical benefits of epoetinalfa therapy in patients with lung cancer[J]. Clin Lung Cancer, 2002, 3(3):180-190.
[12] Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: result of a comprehensive meta-analysis[J]. JNCI J Natl cancer Inst, 2005,97(7): 489-498.
[13] Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials[J]. The Lancet, 2009,373(9674):1532-1542.
[14] Wright J R, Ung Y C, Julian J A, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia[J]. J ClinOncol, 2007, 25(9):1027-1032.
[15] Smith R E, Aapro M S, Ludwig H, et al. Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2008, 26(7):1040-1050.
[16] Untch M, Fasching P A, Bauerfeind I, et al. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, doseintensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetinalfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery [J]. J ClinOncol, 2008,26(Suppl15):Abstract 517.
[17] EMA. EPAR summary for the public, Abseamed epoetin alfa[EB/OL]. (2012-02-07)[2015-06-26].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000727/WC500020663.pdf.
[18] FDA. Highlights prescribing information. Epogen (epoetin alfa). [EB/OL]. (2013-12)[2015-06-26]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103234s5323lbl.pdf.
[19] NCCN.NCCN clinical practice guidelines in oncology. Non-small cell lung cancer (Version 1. 2015)[EB/OL]. (2014-10-26)[2015-06-01]. http://www.nccn.org/patient.